Programmable nucleases have enabled rapid and accessible genome engineering in eukaryotic cells and living organisms. However, their delivery into target cells can be technically challenging when working with primary cells or in vivo. Using engineered murine leukemia virus-like particles loaded with Cas9/sgRNA ribonucleoproteins ("Nanoblades"), we were able to induce efficient genome-editing in cell lines and primary cells including human induced pluripotent stem cells, human hematopoietic stem cells and mouse bone-marrow cells. Transgene-free Nanoblades were also capable of in vivo genome-editing in mouse embryos and in the liver of injected mice. Nanoblades can be complexed with donor DNA for "all-in-one" homology-directed repair or programmed with modified Cas9 variants to mediate transcriptional up-regulation of target genes. Nanoblades preparation process is simple, relatively inexpensive and can be easily implemented in any laboratory equipped for cellular biology.
Introduction
Targeted genome editing tools such as Meganucleases (MGN), Zinc-finger nucleases (ZFN), Transcription Activator-Like Effector Nucleases (TALENs) and more recently the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) have revolutionized most biomedical research fields. Such tools allow to precisely edit the genome of eukaryotic cells by inducing double-stranded DNA (dsDNA) breaks at specific loci. Relying on the cell endogenous repair pathways, dsDNA breaks can then be repaired by Non-Homologous End-Joining (NHEJ) or Homology-Directed Repair (HDR) allowing the removal or insertion of new genetic information at a desired locus. Among the above mentioned tools, CRISPR/Cas9 is currently the most simple and versatile method for genome engineering. Indeed, in the two-component system, the bacterial derived nuclease Cas9 (for CRISPR-associated protein 9) associates with a single-guide RNA (sgRNA) to target a complementary DNA sequence and induce a dsDNA break 1 . Therefore, by the simple modification of the sgRNA sequence, users can specify the genomic locus to be targeted. Consistent with the great promises of CRISPR/Cas9 for genome engineering and gene therapy, considerable efforts have been made in developing efficient tools to deliver the Cas9 and the sgRNA into target cells ex vivo either by transfection of plasmids coding for the nucleases, transduction with viral-derived vectors coding for the nucleases or by direct injection or electroporation of Cas9/sgRNA complexes into cells. Here, we have designed "Nanoblades", a protein-delivery vector based on Friend Murine Leukemia Virus (MLV) that allows the transfer of Cas9/sgRNA ribonucleoproteins (RNPs) to cell lines, primary cells in vitro and in vivo. Nanoblades deliver the ribonucleoprotein cargo in a transient and rapid manner without delivering a transgene and can mediate knock-in in cell lines when complexed with a repair template. Nanoblades can also be programmed with modified Cas9 proteins to mediate transient transcriptional activation of targeted genes.
To further confirm these results, we designed and dosed Nanoblades programmed with a sgRNA widely used in the literature that targets the human EMX1 gene to induce a single cleavage. Indeed, loading of Cas9 into Nanoblades can be monitored from a small aliquot of Nanoblades by performing dot blot or elisa assays using anti Cas9 antibodies (Data not shown). This approach allows an indirect measure of viral titers to normalize the amount of Cas9 protein added to target cells. We then transduced HEK-293T cells with increasing amounts of Nanoblades and measured gene editing from the bulk population 48 hours after transduction (Figure 1c ). Under these conditions, we observed a dose-dependent effect of Nanoblades ranging from 35% of EMX1 editing to 77% of editing at the highest dose of Cas9 (Figure 1c ).
Nanoblade-mediated genome editing in human and mouse primary cells
Genome editing in primary cells and patient-derived pluripotent cells represents a major interest both for basic science and therapeutical applications. However, primary cells are often refractory to DNA transfection and other gene delivery methods. Because Nanoblades are capable of efficient delivery of functional Cas9/sgRNA RNPs into primary fibroblasts, we tested whether they were effective in other primary cell for genome editing. To this aim, Nanoblades targeting EMX1 were used to transduce human induced Pluripotent Stem Cells (hiPSCs). Genome editing at the EMX1 locus was assessed in the bulk cellular population 48 hours after transduction by deep-sequencing of the EMX1 locus (Figure 2a , left panel). As observed, Nanoblades are capable of mediating 67% genome editing at the EMX1 locus in hiPSCs. Similar results were obtained using iPS cells derived from a patient with Duchenne muscular dystrophy bearing a mutation in exon 7 transduced with Nanoblades programmed with a single sgRNA targeting the mutated loci. In this case, we obtained close to 40% of gene editing (Figure 2a , right panel). Notably, hiPSCs treated with EMX1 Nanoblades maintained constant levels of pluripotency markers compared to control cells (Figure 2a , middle panel) thus indicating that their multipotent status does not appear to be affected. Similarly to hiPSCs, mouse bone marrow (BM) cells can be collected and differentiated in vitro into various hematopoietic cell types such as macrophages (Bone marrow derived macrophages or BMDMs) and dendritic cells. Efficient genome editing of specific genes in BM cells would therefore allow for the corresponding pre-existing protein to be degraded during differentiation and obtain a functional knockout. To test this hypothesis, BM cells obtained from GFP transgenic mice 7 were transduced with Nanoblades programmed with a sgRNA targeting the GFP coding sequence. 6 hours after transduction, cells were washed and incubated in presence of Macrophage colony-stimulating factor (MCSF) for 1 week. After this, cells were collected to monitor GFP levels by fluorescence microscopy, FACS and genome editing by T7 endonuclease assay ( Figure 2b ). We consistently obtained close to 75% reduction of GFP expression as measured by FACS analysis and around 60 to 65% genome editing at the GFP locus as measured by T7 endonuclease assays ( Figure 2b ). Importantly, genome editing through Nanoblades did not affect the capacity of BMDMs to respond to LPS as their cytokine expression remains identical to that of untreated control cells (Figure 2b bottom right panel). Nanoblades can therefore be used to inactivate genes in bone marrow cells and study their function in differentiated cells.
Nanoblades efficiency was also tested in a third primary target, primary human hepatocytes. These cells represent a major interest in research and gene therapy due to their proliferative potential and their capacity to colonize and regenerate fully functional tissues. For this, Nanoblades programmed with two sgRNAs targeting the human MYD88 gene (Figure 2c , left panel) were incubated with primary human hepatocytes for 1 hour. Cells were then grown for 24 hours before extracting their genomic DNA and amplifying the region of Myd88 flanking the two targeted sites (Figure 2c , right panel). Our results show significant genome editing in these cells and thus indicate that Nanoblades can be used to mediate specific gene deletion in primary human hepatocytes in a transgene deficient manner. Based on the high efficiency of genome editing in mouse BM cells, we tested whether Nanoblades could also allow genome-editing in human hematopoietic stem cells (HSCs). HSCs are difficult to transduce with VSV-G pseudotyped lentiviral vectors (LVs) because they lack the LDL receptor 8 . However, LVs pseudotyped with the baboon retroviral envelope glycoprotein (BaEV) have been shown to efficiently transduce HSCs 9 . We therefore prepared BaEV and VSV G-pseudotyped Nanoblades programmed with two sgRNAs targeting the human MYD88 gene ( Figure 2c ) and incubated them with human pre-stimulated CD34+ cells. 48 hours post transduction, cells were collected and genome editing was assessed by PCR using primers flanking the excised sequence. As observed, Nanoblades were also able to induce genome editing in these cells (50% genome editing based on TIDE analysis) thus expanding the catalog of primary cells that can be edited using Nanoblades (Figure 2c ). Taken together, our results indicate that Nanoblades are an efficient delivery system to induce rapid and effective genome editing in murine and human primary cells of high therapeutic value that are notoriously difficult to transfect.
"All-in-one" Nanoblades for homology directed repair. Precise insertion of genetic material (also known as Knock-in) using CRISPR/Cas9 can be achieved through Homology-Directed Repair (HDR). This occurs when a donor DNA template with sequence homology to the region surrounding the targeted genomic locus is provided to cells together with the Cas9/sgRNA RNP. Based on a previous finding showing that retroviral-particles can be complexed with DNA to allow for virus-dependent DNA transfection 10 , we decided to test whether Nanoblades could be directly complexed with a DNA template to mediate HDR in target cells. For this, Nanoblades programmed to target a locus close to the AUG start codon of the human DDX3 gene were complexed to a single-stranded DNA oligomer bearing the FLAG-tag sequence flanked with 46 nucleotide (nt) homology arms corresponding to the region surrounding the start-codon of DDX3 (Figure 3a , left panel). These "All-in-one" Nanoblades were incubated with HEK-293T cells. 48 hours after transduction, HDR was assessed in the bulk cellular population both by PCR and by Western-blotting (using a FLAG-antibody). As observed (Figure 3a , right panel), cells transduced with "All-in-one" Nanoblades showed incorporation of the FLAGtag at the DDX3 locus both genetically and at the level of protein expression. Interestingly, the efficiency of HDR in the bulk population was correlated to the amount of donor DNA template (ranging from 0.01 to 10 pmoles) incubated with Nanoblades ( Figure 3a Knock-in assisted by Nanoblades was also obtained inside the AAVS1 locus which has been descrived as a safe harbor for transgene insertion 11 . For this we designed a dsDNA template of 4 Kb bearing the puromycin resistance gene with homology arms to the AAVS1 locus. After transduction of HEK-293T cells with Nanoblades complexed with this template, single-cell derived clones were selected with puromycin. A PCR-assay revealed that 5 out of 6 puromycin-resistant clones had the puromycin cassette inserted at the AAVS1 locus ( Supplementary Figure 3) . Taken together, our results show that Nanoblades can be used for the precise insertion of genetic material through HDR with no requirement of any transfection reagent to introduce the donor DNA template.
Nanoblades confer low off-target genome-editing
A major concern regarding the use of CRISPR/Cas9-mediated gene editing for gene therapy purposes resides in the potential off-target effects that can occur at genomic loci that are similar in sequence to the original target. Interestingly, several reports have shown that transient delivery of the Cas9/sgRNA complex by injection or RNP transfection generally leads to reduced off-target effects as compared to constitutive expression of Cas9 and sgRNA from DNA transfection experiments 12 . Since Nanoblades deliver the Cas9/sgRNA complex in a dose-dependent and transient fashion, we tested whether they could also lead to reduced off-target effects when compared to classical DNA transfection. For this, we developed an approach similar to that described by Fu and colleagues 13 by creating a series of HEK-293T reporter cell lines transduced with different versions of a GFP transgene bearing silent point mutations located in the sgRNA target site (Figure 3b , right panel). These cells were either transfected with plasmids coding for Cas9 and the sgRNA targeting the GFP or transduced with Nanoblades programmed with the same sgRNA. 96 hours after transfection/transduction, cells were collected and GFP expression was monitored by FACS ( Figure 3b , left panel). As expected, GFP expression from cells bearing the wild-type GFP sequence (No Mismatch) was efficiently repressed both after Nanoblades transduction (close to 80% repression) and DNA transfection (close to 60% repression) (Figure 3b, left panel "No Mismatch"). Strikingly, when 2 mismatches were introduced in the target site, Nanoblades were no longer able to efficiently repress GFP expression (20% compared to control) while GFP expression from transfected cells was still reduced to levels similar to that of the GFP bearing a perfect match with the sgRNA. Interestingly, the presence of 3 or 4 mismatches totally abolished GFP inactivation in Nanoblades-treated cells while cells transfected with the Cas9 and sgRNA plasmids still displayed a mild inhibition of GFP expression ( Figure 3b see 3 
and 4 Mismatches).
To complement these results, we further tested for genomic off-target effects using the well-characterized sgRNA targeting human EMX1. Off-targets for this sgRNA have been extensively studied using T7 endonuclease assays and high-throughput sequencing approaches 14 . We PCR-amplified the EMX1 locus and one of the previously described EMX1 genomic off-target loci occurring at the intron of MFAP1 14 in cells treated for 72 hours with Nanoblades programmed with the EMX1 sgRNA or transfected with a DNA construct coding for Cas9 and the EMX1 sgRNA. We then assessed genome-editing on each sample by high-throughput sequencing (Figure 3c) 15 . Editing at the on-target site was efficient in Nanoblade-treated cells (75% in average) and to a less extend in cells transfected with the DNA coding for Cas9 and the sgRNA (53% in average) ( Figure 3c , left panel). As expected, small INDELs (insertions and deletions) occurred close to the expected Cas9 cleavage site located 3nt upstream the PAM sequence both in Nanoblades-treated and in DNA transfected cells (Supplementary figure 4) . Surprisingly, in spite of the higher editing efficiency at the on-target site, we could not detect any significant editing at the MFAP1 off-target site in Nanoblades-treated cells (Figure 3c , right panel). In contrast, cells transfected with the DNA coding for Cas9 and the sgRNA displayed close to 6% editing at the off-target site (Figure 3c , right panel) and had INDELs at the expected cut site (Supplementary figure 4) . Taken together, our results indicate that similarly to other protocols that lead to transient delivery of the Cas9/sgRNA RNP, Nanoblades display low off-target effects.
Targeted transcriptional activation through Nanoblades
Having shown efficient genome editing using Nanoblades loaded with the catalytically active Cas9, we decided to test whether Nanoblades could also deliver Cas9 variants for applications such as targeted transcriptional activation. To this aim, we fused the Cas9derived transcriptional activator (SP-dCas9-VPR) 16 to Gag from MLV and expressed the fusion protein in producer cells together with a control sgRNA or different combinations of sgRNAs targeting the promoter region of human Titin (TTN) as previously described 16 ( Figure 3d , left panel). Nanoblades loaded with SP-dCas9-VPR were then incubated with MCF-7 cells and induction of TTN measured by quantitative PCR (normalized to GAPDH and 18S rRNA expression). As observed (Figure 3d , right panel), when 2 different sgRNAs were used in combination, TTN transcription was stimulated from 50 to 200 fold compared to the control situation. Interestingly, when combining the 4 different sgRNAs in a single VLP, we obtained up to 400 fold transcription stimulation of TTN after 4 hours of transduction. Similar results were obtained at longer time points (Data not shown). Our results therefore suggest that in spite of the large molecular size of the SP-dCas9-VPR (predicted at 224kDa alone and 286kDa when fused to MLV Gag), neither its encapsidation within VLPs nor its delivery and function within target cells are impaired.
Nanoblade-mediated transduction of zygotes for generating transgenic mice
CRISPR/Cas9 has been extensively used to generate transgenic animals through microinjection of zygotes with DNA coding for Cas9 and the sgRNA or with the synthetic sgRNA and a Cas9 coding mRNA or directly with the preassembled Cas9/sgRNA RNP 17 . However, all these options require injection into the pronucleus or the cytoplasm of zygotes, which can significantly impact their viability. Moreover, in some species, pronucleus and even cytoplasmic microinjection can be technically challenging. Because Nanoblades are programmed to fuse their membranes with cellular ones similarly to retroviral and lentiviral vectors, we reasoned that they could also transduce murine zygotes without requiring intracellular microinjection. To test this hypothesis, VLPs loaded with the mCherry protein (instead of Cas9) were produced and injected in the perivitelline space of 1-cell embryos (Figure 4a , top panel). The injected embryos were harvested after 24 hours (2-cell embryos) or 80 hours (blastocysts) for fluorescence analysis (Figure 4a , bottom panel) indicating that VLPs remain mainly in the perivitelline at early stages and subsequently deliver their content into most cells of the developing embryo. Based on these results, Nanoblades programmed with a sgRNA targeting the YFP coding sequence were produced and injected in the perivitelline space of single-cell embryos obtained from YFP transgenic mice 18 Transduced embryos were implanted into pseudopregnant females and carried to term. Importantly, we did not observe any significant effect of perivitelline injection on embryo viability. Screening of YFP editing performed by T7 endonuclease assay revealed that 4 out of 8 founder animals displayed significant YFP editing ( Figure  4b , top panel) that ranged between 5 and 25% based on Tide analysis of the PCR amplicons and high-throughput sequencing (Data not shown). When 3 out of the 4 founder animals were mated with wild-type mice, we found that the mutant edited allele could be successfully transmitted to the next generation as shown by T7 endonuclease assays on the YFP gene ( Figure 4b, bottom panel) . Surprisingly, even though we were expecting each F1 individual to bear a single type of mutation in the YFP locus (since only one allele should be transmitted from the founder animal), Tide analysis of the YFP locus from F1 mice indicated that each individual beared a large diversity of YFP mutations (Data not shown). These results suggests that the initial mice strain contains multiples copies of the YFP transgene (a typical feature in transgenic mice obtained from DNA injection procedures). This was further confirmed by quantitative PCR experiments performed on genomic DNA obtained from the parental mouse strain, which indicated an average of 35 copies of the YFP per cell (Data not shown).
To further confirm the ability of Nanoblades to mediate genome editing in mouse embryos, we designed a sgRNA targeting the loxP sequence that could mimic the action of the Cre recombinase by removing a loxP flanked cassette (Figure 4c , left panel). As a first test, these Nanoblades were tested in primary bone marrow cells derived from R26R-EYFP transgenic mice bearing a single-copy of the YFP transgene under control of a "lox-stoplox" cassette 19 . As a control, we prepared VLPs loaded with Cre (instead of the Cas9 protein) that should efficiently remove the loxP cassette to induce YFP expression. As expected, Cre-loaded VLPs were able to induce YFP expression in 90% of the bone marrow cells derived from the R26R-EYFP mice (Figure 4c 
Discussion
Gene alteration by CRISPRs or other gene editing systems should ideally be achieved in cells or organism by a fast and precise method to limit toxicity of the modus operandi and possible off-target effects due to a sustained expression of effectors. In this regard, extensive efforts have been recently described to vehicle Cas9/sgRNA RNPs in cultured cells and in vivo by non-coding material including Nanocarriers 20 , optimized transfection reagents 12 , or lentivirus-derived particles 21 . This work describes and characterizes original Virus-Like particles to efficiently vectorize the CRISPR/Cas9 system into primary cells embryos, animal and embryos. These noncoding agents -we called herein Nanoblades-incorporate the Cas9 endonuclease into their internal proteic structure. Beyond delivery of Cas9/sgRNA complexes, we show that Nanoblades can be complexed with reparation templates to mediate homologousrecombination-based knock-in in cultured cells. The molecular basis of this technology is the fusion of Cas9 from Streptococcus pyogenes to Gag from Murine Leukemia Virus. Expressed with other components of viral assembly and construct encoding gRNA(s), this molecule can bind sgRNAs into producer cells, forms RNP complexes and cohabits with Gag and Gag-Pol within particles. We indeed show that robust packaging of sgRNAs into Nanoblades depends on their interaction with Gag::Cas9 ( Supplementary Figure 1d ). RNA-seq analysis of Nanoblades targeting the GFP gene revealed that gRNA-GFP was one of the most represented species detected in particles after small cellular RNAs, illustrating that packaging of sgRNAs through Cas9 is an active and efficient process ( Supplementary Figure 2) . Similarly to cell-derived particles including most viral vectors, Nanoblades incorporate diverse biomaterials from producer cells, including proteins and cellular RNAs that could be virtually responsible for the transmission of undesired effects. To characterize Nanoblades composition, Mass Spectrometry was performed and give an overview of main proteins transmitted in recipient cells ( Supplementary Figure 2) . Among the gene ontology terms pointed out by this analysis, plasma membrane terms were particularly enriched which is consistent with the vesicular nature of Nanoblades. As previously described for retroviral-VLPs 22 , characterization of RNA content revealed that Nanoblades contain thousands of individual cellular mRNA species, most of these being encapsidated stochastically, in proportion to their abundance in the producer cell. We found that transcripts overexpressed for production purposes (GAG, VSV-G..) represent less than 0,4% ot Nanoblades RNAs ( Supplementary Figure 2) supporting the notion that their expression in recipient cells is null or marginal. While we cannot exclude the fact that VLPs may be responsible for some cellular responses -depending on recipient cell types-, efficient doses of Nanoblades were globally harmless for most primary cells we tested. In our effort to exploit the retroviral nature of Nanoblades, we explored diverse pseudotyping options (Supplementary Figure 5 ) and finally focussed on the use of an original mixture of two envelopes (VSV-G plus BRL), a recipe that we have optimized (Supplementary Figure  5 ) and which systematically displayed the best cleavage results in most recipient cells. Since efficient Nanoblades can be produced with envelopes fusing at the plasma membrane or in endosomes, we suppose that both entry mechanisms can support the delivery of active RNPs and that both of them are used by VSV-G/BRL Nanoblades. Depending on the cellular target, it may be imaginable to equip surface of VLPs with envelopes from Measles virus 23 , influenza virus 24 or other targeting systems 25, 26 to restrict or improve Cas9 delivery to certain cell types.
Next generation-Nanoblades may also benefit from the continual evolutions of Cas9derivatives that can support fusion with Gag from MLV ( Figure 3 ) and could be adapted to other gene-editing targetable nucleases like Cpf1 nucleases 27 . We also noted that Nanoblades can be engineered to accommodate other proteins/RNAs in addition to Cas9-RNPs and serve as multifunctional agents. Nanoblades capable of delivering both Cas9-RNPs and a reverse-transcribed template that can serve for reparation by homologousrecombination could be envisioned. As illustrated in our work, Nanoblades production can be easily customized by replacement or association of constructs which encode sgRNAs into producer cells. Up to 4 different sgRNAs can be multiplexed in dCas9-VPR Nanoblades (Figure 3 ) and we commonly used couples of sgRNAs within a single preparation to mediate deletions. We noted that this modus operandi is preferable to the pooling of preparations of two particle types, each of them programmed with a single sgRNA. Multiplexing of sgRNAs may also allow the introduction of an additional sgRNA targeting a specific gene that will allow selection of cells efficiently edited by Nanoblademediated CRISPR 28 . This versatility allows any laboratory equipped with BSL2 facilities to generate its own batches of particles. Beyond cell lines, our VLP-based technique provides a powerful tool to mediate gene editing in primary cells including macrophages, hiPSCs, human hematopoietic progenitors and primary hepatocytes. We have shown that Nanoblade injection into the perivitelline space of mouse-zygotes was particularly harmless for the recipient cells since none of the injected zygotes were affected in their development after treatment. Generation of transgenic animals upon perivitelline space injection of VLPs could be adapted to other species, including larger animals for which the number of zygotes is limitant.
Considering the examples provided in our work, we believe that Nanoblade technology will facilitate gene editing for therapeutical purposes and the rapid generation of primary celltypes harboring genetic diseases, humanized-liver mouse models and transgenic animal models.
Methods

Cell culture
Gesicle Producer 293T (Clontech 632617), U2OS cells and primary human fibroblasts (Coriell Institute, GM00312) were grown in DMEM supplemented with 10% fetal calf serum (FCS). Human induced Pluripotent Stem Cells (hiPSCs) were obtained and cultured as described in 29 . Bone marrow-derived Macrophages (BMDMs) were differentiated from bone marrow cells obtained from wild-type C57BL/6 mice. Cells were grown in DMEM supplemented with 10% FCS and 20% L929 supernatant containing Macrophage colony-stimulating factor (MCSF) as described in 30 . Macrophages were stimulated for the indicated times with LPS (Invivogen) at a final concentration of 100 ng/ml.
CD34+-cell sample collection, isolation and treatment with Nanoblades.
Cord blood (CB) samples were collected in sterile tubes containing the anti-coagulant, citrate-dextrose (ACD, Sigma, France) after informed consent and approval was obtained glycoprotein (BaEVRless) 9 (0.7µg) were cotransfected and supernatants were collected from producer cells after 40 hours. For production of serum-free particles, medium was replaced 24 hours after transfection by 10ml of Optimem (Gibco) supplemented with penicillin-streptomycin. Nanoblade-containing medium was clarified by a short centrifugation (500 xg 5 min) and filtered through a 0,8µm pore-size filter before ultracentrifugation (1h30 at 96,000 xg). Pellet was resuspended by gentle agitation in 100µl of cold 1X PBS. Nanoblades were classically concentrated 100-fold. X-Nanoblades referred as Nanoblades loaded with gRNA(s) targeting the x-gene. To dose Cas9 packaged into particles, Nanoblades or recombinant Cas9 (New England Biolabs) were diluted in 1X PBS and serial dilutions were spotted onto a Nitrocellulose membrane. After incubation with a blocking buffer (nonfat Milk 5%w/v in TBST), membrane was stained with a Cas9 antibody (7A9-3A3 clone, Cell signaling) and revealed by a secondary antiMouse antibody coupled to horseradish peroxidase. Cas9 spots were quantified by Chemidoc touch imaging system (Biorad).
Combination of Nanoblades with ssDNA and dsDNA ssDNA (DDX3): 15µl of concentrated DDX3-Nanoblades (2µM Cas9) were mixed with 10µl of 1X PBS containing 8µg/ml of polybrene supplemented with 5µl of each dilutions of the Flag-DDX3 primer, best results being obtained with the higher concentration (5µl of primer at 100pmol/µl). This 'all-in-one' complex was incubated 15 min at 4°C and the 30µl were added onto the medium (400µl+polybrene 4µg/ml) of HEK-293T cultivated in a 12-wellplate (200,000 cells plated the day before). After two hours, the transduction medium was supplemented with 1ml of DMEM 10% FCS. 40 hours after VLP-treatment, cells were passaged for amplification and analysis of the genetic insertion of the flag sequence upstream the DDX3 gene and Western-blot analysis were performed 72 hours later. Sequence of the Flag-DDX3 primer (HPLC-purified): 5'-ACTCGCTTAGCAGCGGAAGACTCCGagTTCTCGGTACTCTTCAGGGATGGA CTACAAGGACGACGATGACAAGagTCATGTGGCAGTGGAAAATGCGCTCGGGCTGGA CCAGCAGGTGA-3' dsDNA (AAVS1): 20ul of concentrated nanoblades were complexed with 500ng of dsDNA in a total volume of 60 microliter of PBS with polybrene at a final concentration of 4ug/ml. After 15 minutes of incubation on ice, complexes were used to transduce HEK293T cells plated the day before at 100000 cells in a 24-well plate in medium supplemented with polybrene (4ug/ml). Two days latter cells were trypsined and replated in a 10cm dish before Puromycin selection (0,7ug/ml). Single-cell derived clones were next isolated and cultivated in a 12w plates before PCR analysis performed on genomic DNAs (500 ng). Primers used were: AAVS1forward:5'-TCCTGAGTCCGGACCACTTTGAG-3' Puromycin reverse:5'-GATCCAGATCTGGTGTGGCGCGTGGCGGGGTAG-3' EMXgene forward 5'-TTCTCTCTGGCCCACTGTGTCCTC-3' EMXgene reverse 5'-AGCCCATTGCTTGTCCCTCTGTCAATG-3'.
T7 endonuclease assay
Genomic DNA was extracted from VLP-treated cells using the Nucleospin gDNA extraction kit (Macherey-Nagel). 150ng of genomic DNA was then used for PCR amplification. PCR products were diluted by a factor 2 and complemented with Buffer 2 (New England Biolabs) to a final concentration of 1X. Diluted PCR amplicons were then heat denatured at 95°C and cooled down to 20°C with a 0.1°C/second ramp. Heteroduplexes were incubated for 30 minutes at 37°C in presence of 10 units of T7 Endonuclease I (NEB). Samples were finally run on a 2.5% agarose gel or on a BioAnalyzer chip (Agilent) to assess editing efficiency.
Immunofluorescence, antibodies and imaging
Cells were fixed in 1X PBS supplemented with 4% of paraformaldehyde (PFA) for 20 min, washed three times with 1X PBS and permeabilized with 0.5% Triton X-100 for 4.5 min. Cells were incubated with primary antibodies overnight at 4°C. Primary antibodies used are: rabbit yH2AX (1:1000; Abcam 81299) and mouse RNA pol I RPA194 (1:500; Santacruz sc48385). Cells were washed three times in 1X PBS, followed by incubation of the secondary antibodies conjugated to Alexa 488 or 594 used at a 1:1000 dilution (Life Technologies) for 1 hour at room temperature. After three 1X PBS washes, nucleus were stained with Hoechst 33342 at 1μg/ml for 5 min. The coverslips were mounted in Citifluor medium (AF1, Citifluor, London, United Kingdom). Cells were observed under a Leica DM6000. At least 100 cells were counted in each indicated experiment. Averages and standard deviation values were obtained from three independent biological replicates.
Mouse experiments
All experiments were performed in accordance with the European Union guidelines for approval of the protocols by the local ethics committee (Authorization Agreement C2EA 15, "Comité Rhône-Alpes d'Ethique pour l'Expérimentation Animale", Lyon, France.
Northern-blot of sgRNAs 2µg of total RNA extracted from Nanoblades or Nanoblade-producing cells were run on a 10% acrylamide, 8M Urea, 0.5X TBE gel for 1 hour at 35watts. RNAs were then transferred onto a Nitrocellulose membrane (Hybond Amersham) by semi-dry transfert for 1 hour at 300mA in 0.5X TBE. The membrane was UV-irradiated for 1 minute using a stratalinker 1800 and then baked at 80°C for 30 min. The membrane was then incubated in 50ml of Church Buffer (125mM Na2HPO4 , 0.085% Phosphoric Acid, 1mM EDTA, 7% SDS, 1%BSA) and washed twice in 10ml of Church buffer. The 5' P32-labeled (1x107cpm total) and heat-denatured ssDNA probe directed against the constant sequence of the guideRNA (sequence of the probe 5'GCACCGACTCGGTGCCACTTTTTCAAGTTGATAACGGACTAGCCTTATTTTAACTTGC TATTTCTAGCTCTA3') was diluted in 10ml of Church buffer and incubated with the membrane overnight at 37°C. The membrane was washed four times in 50ml of wash buffer (1X SSC + 0.1% SDS) before proceeding to phosphorimaging. 31. Zhu, L. J., Holmes, B. R., Aronin, N. & Brodsky, M. H. CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems. PloS One 9, e108424 (2014). b.
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